Page 205 - Mployee Wellness Programs News Today

Providers are, in many cases, getting the equivalent of a Russian nesting doll of third-party risks whenever they acquire a complex new technology solution. Cybersecurity supply chain risk management is the process of identifying and mitigating potential risks that may arise from these third-party products and services within an organization's IT infrastructure.

Atacicept, a Vera Therapeutics drug in development for the rare kidney disease immunoglobulin A nephropathy, is on its way to a pivotal test after achieving the main goal of a mid-stage clinical trial. But the results still fall short of data recently reported by a competitor that is addressing the same disease target.

Withings announced that it is developing a miniaturized platform that can analyze urine at home. The device, called U-Scan, sits within a toilet bowl and assesses specific biomarkers found in urine.

Butler Health System and Excela Health, both based in Pennsylvania, have merged to form a five-hospital system that is now the third largest in the state. The new health system will generate more than $1 billion in revenue and serve a population of 750,000 in western Pennsylvania, the organizations said.

The partnership is with Nextera Healthcare, a Colorado-based direct primary care provider. Nextera will join Hint Health's Hint Connect platform, a network of direct primary care providers for employers and third-party administrators.

While more work needs to be done, the current research into new delivery platforms for nitric oxide is extremely promising. We hope to see the molecule play an increasingly prominent role in treatment and prevention strategies for common infections – and in so doing help provide greater access to healthcare globally.

Several experts look for mental health startups that have conducted rigorous randomized controlled trials. Some of these companies include Ginger, Calm and Woebot.

It’s critical for medical science liaisons (MSLs) and medical affairs teams to build lasting relationships with key opinion leaders (KOLs). And in our increasingly digital-focused world of healthcare, regional and local influencers matter just as much as traditional KOLs. These relationships have a direct impact on the success of clinical trials, bringing treatments to market, and reaching broader and more diverse patient populations. Yet, recent industry data shows that MSLs struggle with id...

Eli Lilly is paying $55 million up front to begin an alliance with Capsida Biotherapeutics pursuing gene therapies for central nervous system disorders. Capsida’s technology enables the delivery of a gene therapy to a single organ or multiple organs, a capability that could bring such treatments to a wider range of diseases.

We expect 2023 to be a pivotal year for the industry, as the accelerated acceptance of virtual care and demographic trends, such as an aging population, increasing chronic illnesses and healthcare worker shortages, sustain demand for medtech-enabled solutions.